Drug intelligence / Profile preview

AMA003

Development stage: Preclinical
Lead developer: Amarna Therapeutics
Modality: Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics, Gene Editing → Gene Therapies, Gene Addition/Replacement → Gene Therapies
Administration: Parenteral

Overview

**AMA003** is a gene therapy under development by Amarna Therapeutics for the treatment of multiple sclerosis (MS). Its mechanism of action involves gene transference and RNA interference, with additional effects as a vascular endothelial growth factor (VEGF) expression inhibitor. The therapy targets self-reactive T lymphocytes implicated in MS pathogenesis. It was previously considered for wet age-related macular degeneration but has been discontinued for that indication[1][2][3].

Other names: AMA-003AMA003AMA 003

Targets

MOG (Myelin oligodendrocyte glycoprotein)

Beyond the preview

Go deeper on AMA003.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AMA003.

Explore the full profile